AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 24118351
Drug: Dual-wavelength laser
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual-wavelength laser system treatment (pulsed dye laser and Nd:YAG)
Trial: 9609894
Drug: Liquid meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid meal (5 mg per kilogram of body weight)
Trial: 7005122
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg atenolol
Trial: 21376161
Drug: 17-hydroxyprogesterone caproate
RxNorm normalized name: 6α-Methyl-17α-hydroxyprogesterone acetate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17-hydroxyprogesterone caproate (17Pc), 250 mg weekly injections starting at 16-24 weeks until 34 weeks
Trial: 17429083
Drug: Anakinra (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anakinra (100 mg subcutaneously once daily for 13 weeks)
Trial: 30313028
Drug: LED therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LED therapy with phototherapy sessions
Trial: 23704845
Drug: Culturally adapted
RxNorm normalized name: casein, emmental cultured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Culturally adapted dietary approach and exercise program, delivered through 24 group sessions, with daily food intake and physical activity recording.
Trial: 19909550
Drug: Specific oncological
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific oncological treatment of relapse
Trial: 16780811
Drug: Sarcosine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sarcosine (2 g/day) added to clozapine
Trial: 8777117
Drug: i.v. diamorphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. diamorphine infusions
Trial: 8777117
Drug: s.c. diamorphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: s.c. diamorphine infusions
Trial: 27022636
Drug: Non‐occluding provisional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non‐occluding provisional acrylic reinforced prosthesis within 24 h after implant placement
Trial: 23426385
Drug: tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tranexamic acid (10‐mg/kg‐1 bolus and 10‐mg/kg‐1/h‐1 maintenance dose)
Trial: 12502673
Drug: Isradipine 5
RxNorm normalized name: isradipine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isradipine 5 mg o.d.
Trial: 10552325
Drug: Side-shift therapy
RxNorm normalized name: cured fat, pork side bacon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Side-shift therapy (mean treatment duration 2.2 years)
Trial: 10552325
Drug: Brace treatment
RxNorm normalized name: Brace Relief
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brace treatment (historical cohort, mean brace treatment 3.0 years)
Trial: 20666678
Drug: Adapalene-BPO combination
RxNorm normalized name: Adapalene
DrugBank: Adapalene (DB00210)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adapalene-BPO combination gel
Trial: 19746769
Drug: Adapalene monotherapy
RxNorm normalized name: Adapalene
DrugBank: Adapalene (DB00210)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adapalene monotherapy
Trial: 19746769
Drug: BPO monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BPO monotherapy
Trial: 17324827
Drug: Gel vehicle
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gel vehicle
Trial: 9553291
Drug: Live attenuated
RxNorm normalized name: mumps, live attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live attenuated varicella vaccine combined with standard measles-mumps-rubella vaccine
Trial: 7378989
Drug: Melphalan (MEL)
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Melphalan (MEL) 0.2 mg/kg/day for five days every four weeks
Trial: 7378989
Drug: Melphalan (MEL)
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Melphalan (MEL) plus 5-fluorouracil (FU) 15 mg/kg/day for five days every four weeks
Trial: 7378989
Drug: Melphalan (MEL)
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Melphalan (MEL) plus 5-fluorouracil (FU) and dactinomycin (AC) 0.5 mg daily for five days every four weeks
Trial: 7378989
Drug: Cytoxan (CY)
RxNorm normalized name: Cys
DrugBank: Cysteine (DB00151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cytoxan (CY) 7 mg/kg/day, FU 8 mg/kg/day and AC 0.5 mg/day for five days every four weeks
Trial: 30893159
Drug: 1.5-mL reconstitution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5-mL reconstitution of abobotulinumtoxinA (50 units)
Trial: 30893159
Drug: 2.5-mL reconstitution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5-mL reconstitution of abobotulinumtoxinA (50 units)
Trial: 19011503
Drug: Salmeterol metered
RxNorm normalized name: salmeterol Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol metered dose inhaler 42 microg BID
Trial: 16799816
Drug: High carbohydrate
RxNorm normalized name: High carbohydrate food
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High carbohydrate intake (HC) - 9.3 +/- 0 g CHO kg(‐1) day(‐1)
Trial: 16799816
Drug: Low carbohydrate
RxNorm normalized name: Low carbohydrate beer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low carbohydrate intake (LC) - 0.6 +/- 0.1 g CHO kg(‐1) day(‐1)
Trial: 14719987
Drug: Radiation doses
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radiation doses ≥40 grays (Gy)
Trial: 8712118
Drug: Enalapril 5
RxNorm normalized name: enalapril 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 5 mg plus diltiazem ER 60 mg
Trial: 8712118
Drug: Enalapril 5
RxNorm normalized name: enalapril 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 5 mg plus diltiazem ER 120 mg
Trial: 8712118
Drug: Enalapril 5
RxNorm normalized name: enalapril 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 5 mg plus diltiazem ER 180 mg
Trial: 8712118
Drug: Enalapril 5
RxNorm normalized name: enalapril 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 5 mg plus diltiazem ER 240 mg
Trial: 8712118
Drug: Enalapril 5
RxNorm normalized name: enalapril 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 5 mg alone
Trial: 1827000
Drug: Isradipine (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isradipine (2.5 or 5 mg twice daily)
Trial: 1827000
Drug: Hydrochlorothiazide (12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (12.5 mg or 25 mg twice daily)
Trial: 1827000
Drug: Open-label enalapril
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-label enalapril (2.5 to 10 mg twice daily)
Trial: 17303622
Drug: Diamorphine 70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diamorphine 70 microg ml(‐1) and levobupivacaine (testing interval 0.004%w/v, starting at 0.044%w/v)
Trial: 17303622
Drug: Levobupivacaine 0.044%w/v
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levobupivacaine 0.044%w/v (fixed) and diamorphine (testing interval 7 microg ml(‐1), starting at 70 microg ml(‐1))
Trial: 17303622
Drug: Fixed combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed combination of diamorphine 69.5 microg ml(‐1) (60.5‐78.5) and levobupivacaine 0.044%w/v (0.039‐0.049)
Trial: 15449747
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of low dose morphine with bupivacaine
Trial: 11394734
Drug: Lansoprazole-based triple
RxNorm normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lansoprazole-based triple therapy (LAN 30 mg BID, clarithromycin 500 mg BID, tinidazole 500 mg BID for 1 week, followed by LAN 30 mg BID for 3 weeks)
Trial: 11394734
Drug: Ranitidine bismuth
RxNorm normalized name: RANITIDINE BISMUTH CITRATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine bismuth citrate-based dual therapy (RBC 400 mg BID plus clarithromycin 500 mg BID for 2 weeks, followed by RBC 400 mg BID for 2 weeks)
Trial: 8405743
Drug: Subcutaneous injection
RxNorm normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection into the abdominal wall (SCA)
Trial: 8405743
Drug: Intramuscular injection
RxNorm normalized name: rabies, intramuscular injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection into the thigh (IMT)
Trial: 8405743
Drug: Subcutaneous injection
RxNorm normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection into the thigh (SCT)
Trial: 2965461
Drug: anti‐human HBs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anti‐human HBs immunoglobulin (HB Ig) and HB vaccine
Trial: 18834319
Drug: 48 weeks
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 48 weeks of pegylated interferon-alpha-2a (180 microg per week) plus ribavirin (1000-1200 mg/day) therapy
Trial: 18834319
Drug: 24 weeks
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 24 weeks of pegylated interferon-alpha-2a (180 microg per week) plus ribavirin (1000-1200 mg/day) therapy
Trial: 18834319
Drug: 48 weeks
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 48 weeks of therapy
Trial: 18834319
Drug: 24 weeks
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 24 weeks of therapy
Trial: 10676668
Drug: Marine omega-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marine omega-3 fatty acids (4 g/day)
Trial: 3953429
Drug: Regular verapamil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular verapamil (80 to 120 mg, 3 times a day)
Trial: 3953429
Drug: Sustained-release verapamil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release verapamil (240 to 360 mg once a day)
Trial: 27920513
Drug: Discair® inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discair® inhalation (18 μg once-daily)
Trial: 27920513
Drug: HandiHaler® inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HandiHaler® inhalation (18 μg once-daily)
Trial: 25015763
Drug: 0.25 mg
RxNorm normalized name: biotin 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg repaglinide, oral, twice daily (group A)
Trial: 25015763
Drug: 0.25 mg
RxNorm normalized name: biotin 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg repaglinide, oral, three times daily (group B)
Trial: 15481062
Drug: Oral 6MP
RxNorm normalized name: 2-Amino 6MP
DrugBank: Tioguanine (DB00352)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral 6MP plus prednisone (OP)
Trial: 15481062
Drug: Intravenous 6MP
RxNorm normalized name: 2-Amino 6MP
DrugBank: Tioguanine (DB00352)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous 6MP plus prednisone (IP)
Trial: 15481062
Drug: Oral 6MP
RxNorm normalized name: 2-Amino 6MP
DrugBank: Tioguanine (DB00352)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral 6MP plus dexamethasone (OD)
Trial: 15481062
Drug: Intravenous 6MP
RxNorm normalized name: 2-Amino 6MP
DrugBank: Tioguanine (DB00352)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous 6MP plus dexamethasone (ID)
Trial: 15481062
Drug: Oral 6MP
RxNorm normalized name: 2-Amino 6MP
DrugBank: Tioguanine (DB00352)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral 6MP during consolidation
Trial: 15481062
Drug: Intravenous 6MP
RxNorm normalized name: 2-Amino 6MP
DrugBank: Tioguanine (DB00352)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous 6MP during consolidation
Trial: 10210339
Drug: 4 litres
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 litres of PEG-saline solution and 15 mg of bisacodyl (SELG-4)
Trial: 10210339
Drug: 156 mg
RxNorm normalized name: menthol 0.156 MG/MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 156 mg of sennosides, 15 g of magnesium sulphate, and 2 litres of water (SennMg)
Trial: 10210339
Drug: 156 mg
RxNorm normalized name: menthol 0.156 MG/MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 156 mg of sennosides and 2 litres of PEG-saline solution (SennSELG)
Trial: 7887640
Drug: 3.75 mg
RxNorm normalized name: zopiclone 3.75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.75 mg TAP-144-SR
Trial: 7887640
Drug: 7.5 mg
RxNorm normalized name: biotin 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg TAP-144-SR
Trial: 2240542
Drug: Lignocaine‐prilocaine cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lignocaine‐prilocaine cream applied for 5 minutes
Trial: 2240542
Drug: Lignocaine‐prilocaine cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lignocaine‐prilocaine cream applied for 60 minutes
Trial: 1120946
Drug: Success treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Success treatment for underachievers
Trial: 1120946
Drug: Failure treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Failure treatment for overachievers
Trial: 31298712
Drug: Clinics offering
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinics offering medications for opioid use disorders
Trial: 28668575
Drug: MenC‐TT vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MenC‐TT vaccine
Trial: 28647167
Drug: MenACWY‐TT vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MenACWY‐TT vaccine
Trial: 20955266
Drug: Dutasteride 0.5
RxNorm normalized name: dutasteride 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dutasteride 0.5 mg once daily
Trial: 18828959
Drug: Inhaled human
RxNorm normalized name: insulin, regular, human Inhalation Powder [Afrezza]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled human insulin (EXU)
Trial: 14508195
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of irbesartan 150 mg and fosinopril 20 mg
Trial: 8829189
Drug: Prophylactic antibiotics
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic antibiotics (ceftazidime, amikacine, and metronidazole for 10 days)
Trial: 8829189
Drug: Nonantibiotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonantibiotic treatment
Trial: 1463170
Drug: 6 ml
RxNorm normalized name: ethanol 0.6 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 ml bupivacaine 0.125%
Trial: 1463170
Drug: 8 ml
RxNorm normalized name: ethanol 0.8 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 ml bupivacaine 0.125%
Trial: 1463170
Drug: 10 ml
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml bupivacaine 0.125%
Trial: 30700348
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin sodium combined with magnesium sulfate
Trial: 29844423
Drug: GCS +
RxNorm normalized name: GCS-100
DrugBank: GCS-100 (DB17566)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GCS + Low Molecular Weight Heparin (LMWH) (Group B)
Trial: 27378312
Drug: Watermelon juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Watermelon juice supplementation (300 mL·day−1 for 16 days)
Trial: 19294551
Drug: Desire for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desire for effective treatment
Trial: 12662366
Drug: Energy prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Energy prescription diet (n=16)
Trial: 31601603
Drug: Antibiotic dispensing
RxNorm normalized name: DISPENSING PIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic dispensing from private pharmacies
Trial: 29340623
Drug: Rituximab (RTX)
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab (RTX) - four weekly infusions of 375 mg/m2
Trial: 21996047
Drug: Coenzyme Q10
RxNorm normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Coenzyme Q10 150 mg/d
Trial: 21996047
Drug: Coenzyme Q10
RxNorm normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Coenzyme Q10 60 mg/d
Trial: 16705003
Drug: Systemic steroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic steroids (Methyl prednisolone 0.5 mg/kg/day i.v. in two divided doses)
Trial: 16705003
Drug: Nebulized steroids
RxNorm normalized name: Hydra-Neb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized steroids (Budecort 50 micrograms nebulized every 12 hours)
Trial: 1555499
Drug: Hemodilution (group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemodilution (group I): six venesections of 400 ml each followed by the injection of 500 ml low-molecular dextran (10%)
Trial: 1555499
Drug: Pentoxifylline (group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (group II): 400 mg four times daily by mouth after initial intravenous loading
Trial: 3924216
Drug: Biosynthetic human
RxNorm normalized name: Proinsulin biosynthetic human
DrugBank: Proinsulin human (DB17875)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biosynthetic human insulin (1 mU/kg/min)
Trial: 3924216
Drug: Insulin antibodies
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin antibodies presence
Trial: 3924216
Drug: Insulin action
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin action loss rate
Trial: 3924216
Drug: Moderate concentrations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate concentrations of insulin antibodies
Trial: 26526713
Drug: Etrolizumab (exact
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etrolizumab (exact dosage and duration not specified)
Trial: 20730362
Drug: HVPC(-) group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HVPC(-) group (conventional treatment plus negative polarity HVPC)
Trial: 20730362
Drug: HVPC+ group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HVPC+ group (conventional treatment plus positive polarity HVPC)
Trial: 20730362
Drug: CG (control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CG (control group with conventional treatment)
Trial: 26147635
Drug: Topical tacrolimus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical tacrolimus 0.1% ointment
Trial: 10469709
Drug: 5 mmol/l
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mmol/l taurine
Trial: 10469709
Drug: 1 mmol/l
RxNorm normalized name: cardiopleg/organ preserv no.1 9 mmol-198 mmol-2 mmol-1 mmol/L PERFUSION BOTTLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mmol/l glutamine
Trial: 10469709
Drug: 1 mmol/l
RxNorm normalized name: cardiopleg/organ preserv no.1 9 mmol-198 mmol-2 mmol-1 mmol/L PERFUSION BOTTLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mmol/l glutamine and 5 mmol/l taurine
Trial: 1913008
Drug: Evening primrose
RxNorm normalized name: EVENING PRIMROSE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evening primrose oil 6 g/day
Trial: 1913008
Drug: Olive oil
RxNorm normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olive oil 6 g/day (placebo)
Trial: 26234526
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg resveratrol supplementation
Trial: 9109102
Drug: D-cycloserine (15,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-cycloserine (15, 50, and 150 mg)
Trial: 28025355
Drug: treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: treatment as usual (normal wait-list)
Trial: 21348810
Drug: Oral levosimendan
RxNorm normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral levosimendan
Trial: 16536958
Drug: Perceived patient
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perceived patient demand for antibiotics
Trial: 11712030
Drug: PDGF gel
RxNorm normalized name: PDGF-2
DrugBank: Becaplermin (DB00102)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PDGF gel
Trial: 28939185
Drug: Antibiotic ointment
RxNorm normalized name: CVS Antibiotic Ointment
DrugBank: Polymyxin B (DB00781)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antibiotic ointment
Trial: 8063984
Drug: Intensive, individualized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive, individualized cognitive therapy (10 sessions over 8 weeks)
Trial: 8063984
Drug: Daily gastrointestinal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily gastrointestinal (GI) symptom monitoring (8 weeks)
Trial: 3194864
Drug: 1.25 mg
RxNorm normalized name: menthol 1.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.25 mg terbutaline (five puffs)
Trial: 25323734
Drug: Taurine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taurine (2 g per day orally, divided into two doses, taken 6 h after chemotherapeutic agents)
Trial: 16452592
Drug: Inhaled heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled heparin (50,000 IU, twice daily for 2 weeks)